Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine as an alternative to electroconvulsive therapy for major depressive disorder
2011-001520-37Phase 3Completed
- Sponsor
- Skåne University Hospital
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Skåne University Hospital. Primary endpoint: Antidepressive effect. Started May 2012; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-001520-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001520-37.